Bionyra
Home - Bionyra Pharma
- Headquarters
- Paris
- Business Model
- B2B
- Website
- bionyra.com
About
Bionyra is a Paris and Boston-based clinical-stage biopharmaceutical company developing a pipeline of next-generation antibodies for severe immune-mediated inflammatory diseases. Its lead programs include BYN-002, a TL1A monoclonal antibody in Phase 1 for inflammatory bowel disease; BYN-003, a first-in-class TL1A x IL-23p19 bispecific antibody; and BYN-001, an IL-25 monoclonal antibody for atopic dermatitis, licensed from TrueLab Biopharmaceutical and NovaRock Biotherapeutics. The company launched with a $165 million oversubscribed Series A financing.
Summary
Bionyra is a Biotech company based in Paris, France.
Tech & App Stack
3 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
Altos Labs combines academic science and industry development to create medicines that restore ce...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Specialty pharmaceutical company
BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/bionyra"><img src="https://indexed.vc/api/badge/company/bionyra" alt="Bionyra on Indexed.vc" width="260" height="76" /></a>